Targeting drugs to tumours using cell membrane-coated nanoparticles

Nature Reviews Clinical Oncology, Journal Year: 2022, Volume and Issue: 20(1), P. 33 - 48

Published: Oct. 28, 2022

Language: Английский

---

Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets

Journal of Hematology & Oncology, Journal Year: 2022, Volume and Issue: 15(1)

Published: May 18, 2022

Abstract Immunotherapies like the adoptive transfer of gene-engineered T cells and immune checkpoint inhibitors are novel therapeutic modalities for advanced cancers. However, some patients refractory or resistant to these therapies, mechanisms underlying tumor resistance have not been fully elucidated. Immunosuppressive such as myeloid-derived suppressive cells, tumor-associated macrophages, neutrophils, regulatory (Tregs), dendritic critical factors correlated with resistance. In addition, cytokines secreted by immunosuppressive also mediate progression escape Thus, targeting related signals is promising therapy improve efficacy immunotherapies reverse even certain success in preclinical studies specific types cancer, large perspectives unknown therapies undesirable outcomes clinical patients. this review, we comprehensively summarized phenotype, function, potential targets microenvironment.

Language: Английский

---

Cell membrane coating integrity affects the internalization mechanism of biomimetic nanoparticles

Nature Communications, Journal Year: 2021, Volume and Issue: 12(1)

Published: Sept. 30, 2021

Cell membrane coated nanoparticles (NPs) have recently been recognized as attractive nanomedical tools because of their unique properties such immune escape, long blood circulation time, specific molecular recognition and cell targeting. However, the integrity coating on NPs, a key metrics related to quality these biomimetic-systems resulting biomedical function, has remained largely unexplored. Here, we report fluorescence quenching assay probe coating. In contradiction common assumption perfect coating, uncover that up 90% biomimetic NPs are only partially coated. Using in vitro homologous targeting studies, demonstrate could still be internalized by target cells. By combining simulations with experimental analysis, further identify an endocytic entry mechanism for NPs. We unravel high degree (≥50%) enter cells individually, whereas low (<50%) need aggregate together before internalization. This quantitative method fundamental understanding how will enhance rational designing nanosystems pave way more effective cancer nanomedicine.

Language: Английский

---

Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies

Journal of Experimental & Clinical Cancer Research, Journal Year: 2022, Volume and Issue: 41(1)

Published: Feb. 19, 2022

Abstract Cancer immunotherapy has emerged as a novel cancer treatment, although recent trials have produced suboptimal outcomes, with durable responses seen only in small number of patients. The tumor microenvironment (TME) been shown to be responsible for immune escape and therapy failure. vital component the TME is tumor-associated macrophages (TAMs), which are usually associated poor prognosis drug resistance, including immunotherapies, promising targets immunotherapy. Recently, nanoparticles, because their unique physicochemical characteristics, crucial translational moieties tackling tumor-promoting TAMs that amplify sensitize tumors immunotherapies safe effective manner. In this review, we mainly described current potential nanomaterial-based therapeutic strategies target TAMs, restricting survival, inhibiting recruitment functionally repolarizing tumor-supportive antitumor type. understanding origin polarization role progression prognostic significance was also discussed review. We highlighted evolution chimeric antigen receptor (CAR)-macrophage cell therapy.

Language: Английский

---

Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment

Molecular Therapy, Journal Year: 2022, Volume and Issue: 30(10), P. 3133 - 3154

Published: April 9, 2022

Exosomes have a crucial role in intercellular communication and mediate interactions between tumor cells tumor-associated macrophages (TAMs). Exosome-encapsulated non-coding RNAs (ncRNAs) are involved various physiological processes. Tumor-derived exosomal ncRNAs induce M2 macrophage polarization through signaling pathway activation, signal transduction, transcriptional post-transcriptional regulation. Conversely, TAM-derived promote proliferation, metastasis, angiogenesis, chemoresistance, immunosuppression. MicroRNAs gene silencing by directly targeting mRNAs, whereas lncRNAs circRNAs act as miRNA sponges to indirectly regulate protein expressions. The of tumor-host is ubiquitous. Current research increasingly focused on the microenvironment. On basis "cancer-immunity cycle" hypothesis, we discuss effects immune T cell exhaustion, overexpression programmed death ligands, create immunosuppressive Furthermore, potential applications prospects clinical biomarkers drug delivery systems. Non-coding do not encode proteins but control expression function.1Hombach S. Kretz M. RNAs: classification, biology functioning.Adv. Exp. Med. Biol. 2016; 937: 3-17Crossref PubMed Scopus (346) Google Scholar, 2Chan J.J. Tay Y. Noncoding RNA:RNA regulatory networks cancer.Int. J. Mol. Sci. 2018; 19: 1310Crossref (608) 3Guil Esteller RNA-RNA regulation: coding noncoding players.Trends Biochem. 2015; 40: 248-256Abstract Full Text PDF Scholar Several types ncRNAs, including microRNAs (miRNAs), long (lncRNAs), circular (circRNAs), affect growth, metabolism multiple mechanisms.3Guil 4Anastasiadou E. Jacob L.S. Slack F.J. RNA cancer.Nat. Rev. Cancer. 18: 5-18Crossref (900) 5Goodall G.J. Wickramasinghe V.O. 2021; 21: 22-36Crossref (337) miRNAs 20–25 nucleotide that at level binding 3′ untranslated region (3′ UTR) target thus regulating other cellular processes.6Ha Kim V.N. Regulation microRNA biogenesis.Nat. Cell 2014; 15: 509-524Crossref (3372) Scholar,7Dong H. Lei Ding L. Wen Ju Zhang X. MicroRNA: function, detection, bioanalysis.Chem. 2013; 113: 6207-6233Crossref (823) longer than 200 nucleotides regulation nucleus cytoplasm.8Chen L.L. Linking localization function.Trends 41: 761-772Abstract (592) Scholar,9Quinn Chang H.Y. Unique features biogenesis function.Nat. Genet. 17: 47-62Crossref (2150) modulate stability, translation, translocation mRNAs.9Quinn Scholar,10Statello Guo C.J. Chen Huarte Gene its biological functions.Nat. 22: 96-118Crossref (817) increase mRNA expressions sponging competitive endogenous (ceRNAs), secreted either alone or bound proteins.11Tay Rinn Pandolfi P.P. multilayered complexity ceRNA crosstalk competition.Nature. 505: 344-352Crossref (2450) Scholar,12Lin C. Yang Long cancer: wiring circuitry.Trends 28: 287-301Abstract (330) characterized covalently closed-loop structure without 5′ cap poly(A) tail.13Yu C.Y. Kuo H.C. emerging roles functions their generation.J. Biomed. 2019; 26: 29Crossref (167) Scholar,14Kristensen Andersen M.S. Stagsted L.V.W. Ebbesen K.K. Hansen T.B. Kjems biogenesis, characterization RNAs.Nat. 20: 675-691Crossref (1539) These implicated spongings, interactions, nuclear transcription pre-mRNA splicing.15Wang R. Li N. Jia Pan Liang CircNT5E acts sponge miR-422a glioblastoma tumorigenesis.Cancer Res. 78: 4812-4825Crossref (199) Scholar,16Qian Yu Z. Meng Huang Wang P. significance human cancers.Biochim. Biophys. Acta 1870: 247-260Crossref (0) 40–150 nm extracellular vesicles pathological processes mediating communication.17Hessvik N.P. Llorente A. knowledge exosome release.Cell Life 75: 193-208Crossref (1112) Scholar,18Pegtel D.M. Gould S.J. Exosomes.Annu. 88: 487-514Crossref (793) content exosomes released donor protected from enzymatic hydrolysis.19Abels E.R. Breakefield X.O. Introduction vesicles: cargo selection, content, release, uptake.Cell. Neurobiol. 36: 301-312Crossref (713) 20Mathieu Martin-Jaular Lavieu G. Théry Specificities secretion uptake for cell-to-cell communication.Nat. 9-17Crossref (1420) 21Mashouri Yousefi Aref A.R. Ahadi A.M. Molaei F. Alahari S.K. Exosomes: composition, mechanisms cancer metastasis resistance.Mol. 75Crossref (410) fundamental resistance.21Mashouri 22van Niel D'Angelo Raposo Shedding light vesicles.Nat. 213-228Crossref (2898) 23Zhang D. development, immunity.Biochim. 1871: 455-468Crossref (215) Tumoral secrete microenvironment (TIME).23Zhang Scholar,24Kalluri function cancer.J. Clin. Invest. 126: 1208-1215Crossref (967) (TEXs) immunological activities, polarization, regulation, inhibition natural killer (NK) activity.25Whiteside T.L. progression.Adv. Chem. 74: 103-141Crossref (402) 26Kok V.C. C.C. Cancer-derived exosomes: biomarker development.Int. Nanomed. 2020; 8019-8036Crossref (50) 27Greening D.W. Gopal Xu Simpson R.J. W. cancer.Semin. Dev. 72-81Crossref (401) TEXs also malignancy, suggesting key tumoral cells.28Xie Zhou Fang Su Tu Extracellular immunotherapy.Adv. 6: 1901779Crossref (103) 29Veerman R.E. Güçlüler Akpinar Eldh Gabrielsson Immune cell-derived - therapeutic applications.Trends 25: 382-394Abstract (110) 30Yan Jiang cancer-immunity cycle.Trends 506-517Abstract (46) development immunosuppression attracted increasing attention.31Sun Shi K. Liu Q. Song Yuan Effect applications.Mol. 147Crossref 32Cheng Zhu Peng Exosomal Glioma: 66Crossref (131) 33Xie Dang Yue Zhai Yan Lu cancer.Mol. 37Crossref (134) can be used because high encapsulation efficiency ability transport anti-cancer drugs, agents, nucleic acids, gene-editing systems such CRISPR-Cas9.34Pullan J.E. Confeld M.I. Osborn J.K. Sarkar Mallik carriers therapy.Mol. Pharm. 16: 1789-1798Crossref (76) 35Liu Cheng Delivery strategies CRISPR-Cas9 system applications.J. Control. Release. 2017; 266: 17-26Crossref (257) 36Ghaemi Bagheri Abnous Taghdisi S.M. Ramezani Alibolandi CRISPR-cas9 genome editing targeted therapy.Life 267: 118969Crossref (7) Macrophages phagocytic cells, phenotypes influenced cytokines factors TIME.37Belgiovine D'Incalci Allavena Frapolli Tumor-associated anti-tumor therapies: complex links.Cell. 73: 2411-2424Crossref assume classically activated pro-inflammatory (M1) phenotype an alternatively anti-inflammatory (M2) phenotype.38Orecchioni Ghosheh Pramod A.B. Ley Macrophage polarization: different signatures M1(LPS+) vs. Classically M2(LPS-) Alternatively macrophages.Front. Immunol. 10: 1084Crossref (541) (TAMs) M1 early stages cancer.37Belgiovine In later stage, growth mediators, IL-4, IL-10, TGF-β, expressed TIME, inducing polarization.37Belgiovine M1-M2 highly dynamic reversible. TAMs produce inhibit activity TIME.39Yin Han Zheng B. Zhao SALL4-mediated upregulation miR-146a-5p drives T-cell exhaustion HCC.Oncoimmunology. 8: 1601479Crossref (3) TAM infiltration solid tumors underscores these progression immunosuppression.39Yin 40Ruffell Coussens L.M. resistance cancer.Cancer Cell. 27: 462-472Abstract (800) 41Sica Erreni Porta pathology.Cell. 72: 4111-4126Crossref (352) divided into M2a, M2b, M2c, M2d.42Rőszer T. Understanding mysterious activation markers effector mechanisms.Mediators Inflamm. 2015: 816460Crossref M2a subgroup IL-4 IL-13 produces CD163, CD206, IL1Ra.42Rőszer M2b stimulated complexes bacterial lipopolysaccharide CD86, IL-6, TNF-α.42Rőszer M2c induced glucocorticoids, TGF-β TGF-β; addition, this active against apoptotic cells.42Rőszer M2d subgroup, IL-6 adenosine, secretes (high levels IL-10 low IL-12) vascular endothelial factor (VEGF) angiogenesis.42Rőszer Some pathways switch.41Sica Scholar,43Shapouri-Moghaddam Mohammadian Vazini Taghadosi Esmaeili S.A. Mardani Seifi Mohammadi Afshari J.T. Sahebkar plasticity, health disease.J. Physiol. 233: 6425-6440Crossref (1441) Pro-inflammatory malignant behavior, promotes tumorigenesis evasion.41Sica Therefore, fine-tuned TIME. Tumor tissues may contain mixed populations with spectrum states. However, review, assumed phenotype, described literature.37Belgiovine Increased attention has been given TAMs. polarized support forming cycle which (Figure 1). This review discusses during initiation controlled influence formation TIME based model, application diagnostic prognostic targets. involves networks.38Orecchioni phosphatidylinositol 3-kinase (PI3K)/AKT JAK/STAT factors, transducer activator (STAT) family, peroxisome proliferator-activated receptor-γ (PPARγ), interferon polarization.44Czimmerer Daniel Horvath Rückerl Nagy Kiss Peloquin Budai M.M. Cuaranta-Monroy I. Simandi et al.The STAT6 mediates direct repression inflammatory enhancers limits macrophages.Immunity. 48: 75-90.e76Abstract (112) Scholar,45Vergadi Ieronymaki Lyroni Vaporidi Tsatsanis Akt M1/M2 polarization.J. 198: 1006-1014Crossref (398) Tumors controlling factors. For instance, HPV+ head neck squamous carcinoma (HNSCC), miR-9 was enriched transported macrophages, downregulating PPARδ.46Tong Mao Xie Sun Wei HPV + HNSCC-derived induces increases radiosensitivity.Cancer Lett. 478: 34-44Crossref (23) miR-451/miR-21 were detected primary multiforme (GBM) taken up brain mice, decreasing c-Myc levels. miR-21 miR-451 increased microglia co-cultured GBM heparin reduced effect.47van der Vos K.E. Abels Lai Carrizosa Oakley Prabhakar Mardini O. Crommentuijn M.H. Skog al.Directly visualized glioblastoma-derived transfer microglia/macrophages brain.Neuro Oncol. 58-69Crossref (207) prostate (PCa), let-7a-5p let7-b, -g, -i downregulated integrin-β3, causing PCa migration.48Ferguson Lee Deci Nguyen phenotypic distinct sources: comparative study composition.AAPS 67Crossref lncRNA TUC339 hepatocellular (HCC) promoted leading cytokine production, compromised phagocytosis, decreased co-stimulatory molecule macrophages.49Kogure I.K. Lin W.L. Patel vesicle-mediated novel TUC339: mechanism cancer.Genes 4: 261-272Crossref (239) Scholar,50Li Wu HCC-derived TUC339.Int. 2958Crossref (36) receptor CXCR chemokine pathways, explain underlying regulation.50Li miR-21-5p colorectal (CRC) cells.51Shao Shen al.Colorectal cancer-derived small establish premetastatic niche liver metastasis.Carcinogenesis. 39: 1368-1379Crossref (6) CRC lines SW480, SW620, LoVo injected nude mice significantly macrophages. via TLR7 pre-metastatic survival colonization, ultimately metastasis.51Shao metabolic enzymes. melanoma miR-125b-5p lysosomal acid lipase A switching survival.52Gerloff Lützkendorf Moritz R.K.C. Wersig Mäder Müller L.P. Sunderkötter Melanoma-derived educates associated (LIPA).Cancers. 12: 464Crossref BMP-7, PI3K/AKT pathway.45Vergadi Scholar,53Covarrubias A.J. Aksoylar H.I. Horng Control mTOR signaling.Semin. 286-296Crossref (189) Scholar,54Zhao Kong F.Q. Jie A.D. Y.Q. D.D. Z.Q. al.Macrophage MSR1 BMSC osteogenic differentiation M2-like activating PI3K/AKT/GSK3β/β-catenin pathway.Theranostics. 17-35Crossref (37) Phosphatase tension homolog deleted chromosome ten (PTEN) inhibits AKT dephosphorylating PIP3.45Vergadi Scholar,55Lu PTEN/PI3k/AKT regulates emphysematous mice.Scand. 85: 395-405Crossref (38) bladder regulated inhibiting PTEN enhanced STAT3 expression, promoting migration invasion.56Lin Yin H.B. X.Y. G.M. He W.Y. Gou Bladder cell-secreted activates progression.Int. 56: 151-164PubMed miR-130b-3p, miR-425-5p, miR-25-3p pathway. epithelial-mesenchymal transition (EMT) VEGF metastasis.57Wang Si Cui Qu contribute CXCL12/CXCR4-induced enhancing macrophages.Cancer 474: 36-52Crossref (108) Scholar,58Wang Corrigendum "Exosome-encapsulated macrophages" [Canc. 474 (2020) 36-52].Cancer 2022; 525: 200-202Crossref circFARSA upregulated non-small lung (NSCLC) exosomes.59Chen PTEN/PI3K/AKT metastasis.Cancer Treat. Commun. 100412Crossref (11) ubiquitination degradation PTEN, polarization.59Chen RNA-binding eIF4A3 triggered cyclization EMT NSCLC cells.59Chen STAT1/5 STAT 3/6 respectively.60Zhao Bian Y.Y. Y.J. Ma Y.T. Pei Zeng HuoXueTongFu formula alleviates intraperitoneal adhesion SOCS/JAK2/STAT/PPAR-γ signalling pathway.Mediators 2019: 1769374Crossref (14) Scholar,61Hu Ivashkiv L.B. Crosstalk among Jak-STAT, Toll-like receptor, ITAM-dependent activation.J. Leukoc. 2007; 82: 237-243Crossref (157) members suppressor (SOCS) family.60Zhao miR-29a-3p oral SOCS1/STAT6 signaling.62Cai Qiao Gao Oral carcinoma-derived subtype mediated exosome-enclosed miR-29a-3p.Am. 316: C731-C740Crossref co-culture system, miR-223 cervical (CSCC) CSCC creating positive feedback loop.63Zhang Qian STAT3-miR-223-TGFBR3/HMGCS1 axis modulates carcinoma.Mol. 14: 2313-2331Crossref Moreover, repressed TGFBR3 HMGCS1 UTRs, resulting anchorage-independent growth.63Zhang Hypoxia stimulates secretion, hypoxic trigger HIF1α- HIF2α-dependent manner.64Escribese Casas Corbí A.L. Influence oxygen tensions polarization.Immunobiology. 2012; 217: 1233-1240Crossref Scholar,65Díaz-Bulnes Saiz M.L. López-Larrea Rodríguez R.M. hypoxia ER stress res

Language: Английский

---

A Polymer Multicellular Nanoengager for Synergistic NIR‐II Photothermal Immunotherapy

Advanced Materials, Journal Year: 2021, Volume and Issue: 33(14)

Published: Feb. 26, 2021

Abstract Cell‐membrane‐coated nanoparticles (CCNPs) that integrate the biophysiological advantages of cell membranes with multifunctionalities synthetic materials hold great promise in cancer immunotherapy. However, strategies have yet to be revealed further improve their immunotherapeutic efficacy. Herein, a polymer multicellular nanoengager (SPNE) for synergistic second‐near‐infrared‐window (NIR‐II) photothermal immunotherapy is reported. The consists an NIR‐II absorbing as core, which camouflaged fused derived from immunologically engineered tumor cells and dendritic (DCs) vaccine shell. In association high accumulation lymph nodes tumors, engagement ability SPNE enables effective cross‐interactions among cells, DCs, T leading augmented activation relative bare or tumor‐cell‐coated nanoparticles. Upon deep‐tissue penetrating photoirradiation, eradicates induces immunogenic death, eliciting anti‐tumor immunity. Such effect eventually inhibits growth, prevents metastasis procures immunological memory. Thus, this study presents general cell‐membrane‐coating approach develop photo‐immunotherapeutic agents therapy.

Language: Английский

---

Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy

Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)

Published: April 2, 2024

Abstract Cancer immunotherapy and vaccine development have significantly improved the fight against cancers. Despite these advancements, challenges remain, particularly in clinical delivery of immunomodulatory compounds. The tumor microenvironment (TME), comprising macrophages, fibroblasts, immune cells, plays a crucial role response modulation. Nanoparticles, engineered to reshape TME, shown promising results enhancing by facilitating targeted These nanoparticles can suppress fibroblast activation, promote M1 macrophage polarization, aid dendritic cell maturation, encourage T infiltration. Biomimetic further enhance increasing internalization agents cells such as cells. Moreover, exosomes, whether naturally secreted body or bioengineered, been explored regulate TME immune-related affect cancer immunotherapy. Stimuli-responsive nanocarriers, activated pH, redox, light conditions, exhibit potential accelerate co-application with checkpoint inhibitors is an emerging strategy boost anti-tumor immunity. With their ability induce long-term immunity, nanoarchitectures are structures development. This review underscores critical overcoming current driving advancement modification.

Language: Английский

---

Harnessing anti‐tumor and tumor‐tropism functions of macrophages via nanotechnology for tumor immunotherapy

Exploration, Journal Year: 2022, Volume and Issue: 2(3)

Published: Feb. 25, 2022

Reprogramming the immunosuppressive tumor microenvironment by modulating macrophages holds great promise in immunotherapy. As a class of professional phagocytes and antigen-presenting cells innate immune system, can not only directly engulf clear cells, but also play roles presenting tumor-specific antigen to initiate adaptive immunity. However, tumor-associated (TAMs) usually display tumor-supportive M2 phenotype rather than anti-tumor M1 phenotype. They support escape immunological surveillance, aggravate progression, impede T cell Although many TAMs-modulating agents have shown success therapy multiple tumors, they face enormous challenges including poor accumulation off-target side effects. An alternative solution is use advanced nanostructures, which deliver augment therapeutic efficacy, serve as modulators TAMs. Another important strategy exploitation macrophage-derived components tumor-targeting delivery vehicles. Herein, we summarize recent advances targeting engineering for immunotherapy, (1) direct indirect effects on augmentation immunotherapy (2) strategies macrophage-based drug carriers. The existing perspectives immunotherapies are highlighted.

Language: Английский

---

Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment

Journal of Nanobiotechnology, Journal Year: 2022, Volume and Issue: 20(1)

Published: Dec. 27, 2022

Abstract Synthetic nanoparticles with surface bioconjugation are promising platforms for targeted therapy, but their simple biological functionalization is still a challenging task against the complex intercellular environment. Once synthetic enter body, they phagocytosed by immune cells system. Recently, cell membrane camouflage strategy has emerged as novel therapeutic tactic to overcome these issues utilizing fundamental properties of natural cells. Macrophage, type system cells, plays critical roles in various diseases, including cancer, atherosclerosis, rheumatoid arthritis, infection and inflammation, due recognition engulfment function removing substances pathogens. Macrophage membranes inherit protein profiles biointerfacing source Therefore, macrophage cloaking can protect from phagocytosis Meanwhile, make use correspondence accurately recognize antigens target inflamed tissue or tumor sites. In this review, we have summarized advances fabrication, characterization homing capacity cancers, cardiovascular central nervous microbial infections. Although membrane-camouflaged currently fetal stage development, there huge potential challenge explore conversion mode clinic.

Language: Английский

---

Recent advances in multifunctional nanomaterials for photothermal-enhanced Fenton-based chemodynamic tumor therapy

Materials Today Bio, Journal Year: 2022, Volume and Issue: 13, P. 100197 - 100197

Published: Jan. 1, 2022

Photothermal (PT)-enhanced Fenton-based chemodynamic therapy (CDT) has attracted a significant amount of research attention over the last five years as highly effective, safe, and tumor-specific nanomedicine-based therapy. CDT is new emerging nanocatalyst-based therapeutic strategy for in situ treatment tumors via Fenton reaction or Fenton-like reaction, which got fast progress recent because its high specificity activation by endogenous substances. A variety multifunctional nanomaterials such metal-, metal oxide-, metal-sulfide-based nanocatalysts have been designed constructed to trigger within tumor microenvironment (TME) generate cytotoxic hydroxyl radicals (•OH), efficient killing cells. However, still required enhance curative outcomes minimize side effects. Specifically, efficiency certain CDTs hindered TME, including low levels hydrogen peroxide (H2O2), overexpression reduced glutathione (GSH), catalytic efficacy reactions (pH 5.6-6.8), makes it difficult completely cure cancer using monotherapy. For this reason, photothermal (PTT) utilized combination with efficacy. More interestingly, heating during PTT not only causes damage cells but can also accelerate generation •OH reactions, thus enhancing efficacy, providing more effective when compared Currently, synergistic PT-enhanced both PT properties made enormous theranostics. there no comprehensive review on subject published date. In review, we first summarize treatment. We then discuss potential challenges future development nanocatalytic clinical application.

Language: Английский

---